Abstract:l-3,4-dihydroxyphenylalanine (l-DOPA) is an effective treatment for Parkinson's disease (PD); however, long-term treatment induces l-DOPA-induced dyskinesia (LID). To elucidate its pathophysiology, we developed a mouse model of LID by daily administration of l-DOPA to PD male ICR mice treated with 6-hydroxydopamine (6-OHDA), and recorded the spontaneous and cortically evoked neuronal activity in the external segment of the globus pallidus (GPe) and substantia nigra pars reticulata (SNr), the connecting and output nuclei of the basal ganglia, respectively, in awake conditions. Spontaneous firing rates of GPe neurons were decreased in the dyskinesia-off state (≥24 h after l-DOPA injection) and increased in the dyskinesia-on state (20–100 min after l-DOPA injection while showing dyskinesia), while those of SNr neurons showed no significant changes. GPe and SNr neurons showed bursting activity and low-frequency oscillation in the PD, dyskinesia-off, and dyskinesia-on states. In the GPe, cortically evoked late excitation was increased in the PD and dyskinesia-off states but decreased in the dyskinesia-on state. In the SNr, cortically evoked inhibition was largely suppressed, and monophasic excitation became dominant in the PD state. Chronic l-DOPA treatment partially recovered inhibition and suppressed late excitation in the dyskinesia-off state. In the dyskinesia-on state, inhibition was further enhanced, and late excitation was largely suppressed. Cortically evoked inhibition and late excitation in the SNr are mediated by the cortico-striato-SNr direct and cortico-striato-GPe-subthalamo-SNr indirect pathways, respectively. Thus, in the dyskinesia-on state, signals through the direct pathway that release movements are enhanced, while signals through the indirect pathway that stop movements are suppressed, underlying LID. SIGNIFICANCE STATEMENT Parkinson's disease (PD) is caused by progressive loss of midbrain dopaminergic neurons, characterized by tremor, rigidity, and akinesia, and estimated to affect around six million people world-wide. Dopamine replacement therapy is the gold standard for PD treatment; however, control of symptoms using l-3,4-dihydroxyphenylalanine (l-DOPA) becomes difficult over time because of abnormal involuntary movements (AIMs) known as l-DOPA-induced dyskinesia (LID), one of the major issues for advanced PD. Our electrophysiological data suggest that dynamic changes in the basal ganglia circuitry underlie LID; signals through the direct pathway that release movements are enhanced, while signals through the indirect pathway that stop movements are suppressed. These results will provide the rationale for the development of more effective treatments for LID.

Characterization of graded 6-Hydroxydopamine unilateral lesion in medial forebrain bundle of mice

MPTP-Induced Impairment of Cardiovascular Function

The Effects of Unilateral 6-OHDA Lesion in Medial Forebrain Bundle on the Motor, Cognitive Dysfunctions and Vulnerability of Different Striatal Interneuron Types in Rats

Behavioral effects of 6-hydroxydopamine-induced damage to nigro-striatal pathway and Locus coeruleus as a rodent model of Parkinson's disease.

A Guide to the Generation of a 6-Hydroxydopamine Mouse Model of Parkinson’s Disease for the Study of Non-Motor Symptoms

Mouse Model of Parkinson's Disease with Bilateral Dorsal Striatum Lesion with 6-Hydroxydopamine Exhibits Cognitive Apathy-like Behavior

Evaluation of Parkinson’s Disease in 3 Rat Models Induced by Three Different Unilateral Injections of 6-Hydroxydopamine

1-Methyl-4-phenylpyridinium Stereotactic Infusion Completely and Specifically Ablated the Nigrostriatal Dopaminergic Pathway in Rhesus Macaque.

NMDA receptor remodeling and nNOS activation in mice after unilateral striatal injury with 6-OHDA

The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease

Cortical Regulation of Striatal Projection Neurons and Interneurons in a Parkinson's Disease Rat Model.

PD rat model were established by the injection 6-OHDA into the medial forebrain bundle (MFB) with stereotactic technique

Transient Increases in Neural Oscillations and Motor Deficits in a Mouse Model of Parkinson's Disease

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Evaluation Of A Rat Model Of Parkinson'S Disease By Injection Of 6-Ohda Into The Substantia Nigra

Analysis of m6A modification regulators in the substantia nigra and striatum of MPTP-induced Parkinson’s disease mice

Abnormal Cortico-Basal Ganglia Neurotransmission in a Mouse Model of L-DOPA-Induced Dyskinesia

Alterations of NMDA Receptor Binding in Various Brain Regions among 6-Hydroxydopamine-induced Parkinsonian Rats

Establishment and MRI Analysis of Rat Model of Parkinson's Disease

Alterations of Emotion, Cognition and Firing Activity of the Basolateral Nucleus of the Amygdala after Partial Bilateral Lesions of the Nigrostriatal Pathway in Rats

The PD rat model were established by the injection 6-OHDA into SNC and VTA with stereotactic technique